keepMED™ Ltd., (formerly Ninox Medical) is a medical technology company dedicated to providing disruptive solutions for the treatment of Obstructive Sleep Apnea (OSA).
keepMED is currently developing a wearable device called the keePAP™ for the treatment of OSA. The keePAP is comprised of a lightweight, unobtrusive nasal interface and a miniature battery-operated control unit that make it convenient for both home and travel.
The keePAP is expected to offer a completely new level of comfort and ease of use, resulting in a remarkable improvement in compliance and making it the product of choice for the millions who suffer from OSA.
Board Of Directors
Dr. Ezekiel has held various managerial positions in both start-up and Fortune 500 companies in Israel and in the United States. Until recently he was the President & CEO of Brainsway [TLV: BRIN]. Prior to joining Brainsway, Dr. Ezekiel was the President & CEO of Marval Pharma, a clinical stage company, developing innovative contrast agents for use in X-ray and Computed Tomography (CT) Imaging. Prior to that Dr. Ezekiel was the General-Manager/Vice President of Medtronic Ventor Technologies, a wholly owned subsidiary of Medtronic Inc [NYSE:MDT]. Dr. Ezekiel served as the President and CEO of Ventor Technologies, developing trans-catheter valves for the Cardiology market. Dr. Ezekiel led the company during its acquisition by Medtronic for $325M generating to its investors returns of > X50. Prior to joining Ventor and before returning to Israel, Dr. Ezekiel was the Executive Director of the CT marketing unit at Medrad, Inc., a wholly owned subsidiary of Bayer Healthcare [FWB: BAYN] . Prior to Medrad, Dr. Ezekiel served as the Marketing & Clinical Director of Ultraguide - an Israeli medical device startup that developed image-guided systems. Guy is a Venture Partner at Pitango, Israel’s largest Venture Capital fund with with over $2 billion under management. Guy holds an MD from Ben-Gurion University of the Negev and an MBA (cum laude) from the University of Pittsburgh.
Dr. Guy Ezekiel
Valérie Calenda began her career as research scientist in hematology and virology at the Institut National de la Recherche Médicale (INSERM). After collaborating at a French/USresearch program on HIV at Davis University in California, she joined Transgene, an affiliate of Institut Mérieux focusing on immunotherapy, in 1994 where she was in charge of severalprojects focusing on HIV and Cardiovascular areas until 2000. She then led a spin-off project in cardio-vascular therapeutic area before collaborating with a Paris based seed Venture Capitalfirm. Valérie also managed several biotech clinical-stage product developments within the infectious diseases and oncology disease areas, from pre-IND to Phase 2. This led her to manage both in-licensing and out-licensing activities, including global license agreement and alliance management with Hoffman La Roche, acquisition of biotech assets in Europe and in the US. Valérie joined Merieux Développement as a Partner in January 2010.Valérie received her PhD in Pharmacology from the University of Marseille and . She holds a degree in Hematology and a B.Sc. in Biochemistry-Immunology from the University of Marseille.
Valérie Calenda, PhD
Partner, Merieux Développement
Alex is serial entrepreneur with 28 years of senior management and consulting experience specializing in product development, business development and marketing and sales in the area of medical devices. Prior to founding keepMED, Alex was an independent consultant specializing in interim executive management and business development services to medical device companies. Alex served as CEO of Motorika - an Israel and U.S. based manufacturer of medical robotics equipment for rehabilitation of stroke patients. Earlier in his carrier Alex founded and was a CEO of Myriad Ultrasound system - an Israel and U.S developer and manufacturer of ultrasound equipment for diagnosis of osteoporosis. Alex started his carrier in 1987 as a development engineer and product manager at Mennen Medical. Alex holds a B.Sc. in Electrical and Computers Engineering from the Ben-Gurion University, Beer-Sheva.
Founder and CEO, keepMED
Dr. Daphne Haim-Langford has over 14 years of managerial experience. Daphne has been involved in medical device entrepreneurship and specializes in fundraising,strategic planning, marketing, distribution, reimbursement, and product management in the medical device industry. Prior to joining Xenia, Dr. Haim-Langford was VP Business Development & Marketing at Medingo, an insulin patch pump company which was acquired by Roche. Prior to that, she was General Manager with Per Assist, a Misgav Technology Center portfolio company. Before joining PerAssist, Dr. Haim-Langford was Product Manager for Carmel Biosensor, developing biosensors for glucose and anesthesia. Dr. Haim-Langford is the Chairperson of the Israeli Biomimicry Organization, a nonprofit organization promoting sustainable innovation inspired by nature. She is also a lecturer at the Interdisciplinary Center (IDC) Herzliya Business School. Dr. Haim-Langford holds a Ph.D degree in Biotechnology from Technion and a B.Sc. in Nutrition from Hebrew University (Cum Laude).
Daphne Haim-Langford, PhD,
VP Business Dev, Xenia Ventures
© Copyright 2017 keepMED Ltd. All rights reserved.
The keePAP™ is an investigational device and is limited by U.S. law to investigational use. This product is not currently available for sale or distribution and has not been approved by the U.S. FDA or by any other country’s regulatory authority.
//site by: Pixelfuse.net